Key facts
- It has raised $2.1M; the latest was Later Stage VC ($2.1M) in Oct 2025.
- Notable investors include Cancer-cell, Huiyi Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bio-SF
- ·The full record, as it builds
Funding rounds
No funding rounds for Bio-SF are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bio-SF
Operator of a biomedical testing facility intended to evaluate the efficacy and safety of medical devices, biomaterials, and combination products. The company offers GLP-compliant animal testing, advanced pathology diagnostics, and biocompatibility assessments, enabling medical manufacturers and research institutions to ensure regulatory compliance, product reliability, and clinical readiness.
- Sector
- Healthcare
- HQ
- Changshu, China
- Founded
- 2020
- Employees
- 60
- Website
- bio-safety.com.cn/
- Ownership
- Privately Held (backing)
Bio-SF doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bio-SF shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bio-SF in its N-PORT filings yet. We sweep new filings monthly.